Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Radiation in Metastatic Merkel Cell Carcinoma
NCT03988647Phase 2Terminated
- Sponsor
- Stanford University
- Start
- Jul 2019
- Primary completion
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in Merkel cell carcinoma (MCC), sponsored by Stanford University. Started Jul 2019; status: terminated.
02
Drugs
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT03988647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03988647.